HRP20200930T1 - Lentivirusni vektori - Google Patents
Lentivirusni vektori Download PDFInfo
- Publication number
- HRP20200930T1 HRP20200930T1 HRP20200930TT HRP20200930T HRP20200930T1 HR P20200930 T1 HRP20200930 T1 HR P20200930T1 HR P20200930T T HRP20200930T T HR P20200930TT HR P20200930 T HRP20200930 T HR P20200930T HR P20200930 T1 HRP20200930 T1 HR P20200930T1
- Authority
- HR
- Croatia
- Prior art keywords
- lentiviral vector
- disease
- factor
- transgene
- virus
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims 22
- 108700019146 Transgenes Proteins 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 3
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 3
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 2
- 208000025678 Ciliary Motility disease Diseases 0.000 claims 2
- 108700011014 Congenital Deficiency of Pulmonary Surfactant Protein B Proteins 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims 2
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims 2
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims 2
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims 1
- 102100032300 Dynein axonemal heavy chain 11 Human genes 0.000 claims 1
- 102100031648 Dynein axonemal heavy chain 5 Human genes 0.000 claims 1
- 102100033595 Dynein axonemal intermediate chain 1 Human genes 0.000 claims 1
- 102100033596 Dynein axonemal intermediate chain 2 Human genes 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010074864 Factor XI Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101001016208 Homo sapiens Dynein axonemal heavy chain 11 Proteins 0.000 claims 1
- 101000866368 Homo sapiens Dynein axonemal heavy chain 5 Proteins 0.000 claims 1
- 101000872267 Homo sapiens Dynein axonemal intermediate chain 1 Proteins 0.000 claims 1
- 101000872272 Homo sapiens Dynein axonemal intermediate chain 2 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 241000713325 Visna/maedi virus Species 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 238000011210 chromatographic step Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000009724 equine infectious anemia Diseases 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229940012426 factor x Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 optionally Proteins 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000012794 pre-harvesting Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18845—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mushroom Cultivation (AREA)
Claims (13)
1. Lentivirusni vektor, naznačen time, da je pseudotipiziran s hemaglutinin-neuraminidazom (HN) i proteinima fuzije (F) iz respiratornog paramiksovirusa, pri čemu navedeni lentivirusni vektor obuhvaća hibridni ljudski CMV aktivator/EF1a (hCEF)-promotor i jedan transgen, te time, da lentivirusnom vektoru nedostaje jedan (bilo koji) intron koji je pozicioniran između navedenog promotora i navedenog transgena.
2. Lentivirusni vektor prema patentnom zahtjevu 1, naznačen time, da se lentivirusni vektor odabire iz skupine koja se sastoji od vektora ljudskog virusa imunodeficijencije (HIV- Human immunodeficiency virus), vektora majmunskog virusa imunodeficijencije (SIV-Simian immunodeficiency virus), vektora mačjeg virusa imunodeficijencije (FIV-Feline immunodeficiency virus), vektora virusa infektivne anemije porodice konja (EIAV-Equine infectious anaemia virus), i vektora virusa Visna/Maedi;
pri čemu je lentivirusni vektor poželjno SIV-vektor.
3. Lentivirusni vektor prema patentnom zahtjevu 1 ili 2, naznačen time, da respiratorni paramiksovirus je virus Sendai.
4. Lentivirusni vektor prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se transgen odabire od sljedećih:
(a) sekrecijski terapeutski protein, opcionalno, alfa-1-antitripsin (A1AT), faktor VIII, tenzidni protein B (SFTPB), faktor VII, faktor IX, faktor X, faktor XI, faktor von Willebrand, faktor stimuliranja kolonije granulocita i makrofaga (GM-CSF), ili monoklonsko protutijelo protiv infektivnog agensa; ili
(b) CFTR, DNAH5, DNAH11, DNAI1 ili DNAI2.
5. Lentivirusni vektor prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da:
(a) transgen kodira CFTR;
(b) transgen kodira A1AT; ili
(c) transgen kodira FVIII.
6. Lentivirusni vektor prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da transgen kodira CFTR.
7. Postupak proizvodnje lentivirusa definiranog prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da postupak obuhvaća sljedeće korake:
(a) uzgajanje stanica u suspenziji;
(b) transficiranje stanica s jednim ili više plazmida;
(c) dodavanje nukleaze;
(d) sakupljanje lentivirusa;
(e) dodavanje tripsina; i
(f) pročišćavanje.
8. Postupak prema patentnom zahtjevu 7, naznačen time, da:
(i) koraci (a) do (f) se provode slijedom uzastopno;
(ii) stanice su HEK293T-stanice ili 293T/17-stanice;
(iii) dodavanje nukleaze slijedi u stadiju prije sakupljanja;
(iv) dodavanje tripsina slijedi u stadiju nakon sakupljanja; i/ili
(v) korak pročišćavanja obuhvaća korak kromatografije.
9. Lentivirusni vektor prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se upotrebljava u postupku liječenja bolesti.
10. Lentivirusni vektor za uporabu prema patentnom zahtjevu 9, naznačen time, da se kod bolesti radi o plućnoj bolesti koja je odabrana od sljedećih:
cistična fibroza (CF); primarna cilijarna diskinezija (PCD); pomanjkanje tenzidnog proteina B (SP-B-deficijencija); alfa-1-antitripsin-deficijencija (A1AD); plućna alveolska proteinoza (PAP); i kronična opstruktivna plućna bolest (KOPB).
11. Lentivirusni vektor za uporabu prema patentnom zahtjevu 9, naznačen time, da:
(a) bolest koja se treba liječiti je CF;
(b) bolest koja se treba liječiti je A1AT-deficijencija; ili
(c) bolest koja se treba liječiti je hemofilija, pri čemu, opcionalno, transgen je faktor VIII.
12. Stanica domaćina, naznačena time, da sadrži vektor u skladu s bilo kojim od patentnih zahtjeva 1 do 6.
13. Pripravak, naznačen time, da sadrži vektor u skladu s bilo kojim od patentnih zahtjeva 1 do 6, i farmaceutski prihvatljiv nosač.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1409089.8A GB2526339A (en) | 2014-05-21 | 2014-05-21 | Lentiviral vectors |
| EP15720762.2A EP3145949B1 (en) | 2014-05-21 | 2015-04-23 | Lentiviral vectors |
| PCT/GB2015/051201 WO2015177501A1 (en) | 2014-05-21 | 2015-04-23 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200930T1 true HRP20200930T1 (hr) | 2020-09-18 |
Family
ID=51135270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200930TT HRP20200930T1 (hr) | 2014-05-21 | 2020-06-10 | Lentivirusni vektori |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10704061B2 (hr) |
| EP (1) | EP3145949B1 (hr) |
| JP (1) | JP6637444B2 (hr) |
| AU (1) | AU2015263150B2 (hr) |
| CA (1) | CA2947125C (hr) |
| CY (1) | CY1123413T1 (hr) |
| DK (1) | DK3145949T3 (hr) |
| EA (1) | EA038966B1 (hr) |
| ES (1) | ES2805045T3 (hr) |
| GB (1) | GB2526339A (hr) |
| HR (1) | HRP20200930T1 (hr) |
| HU (1) | HUE051269T2 (hr) |
| LT (1) | LT3145949T (hr) |
| ME (1) | ME03789B (hr) |
| PL (1) | PL3145949T3 (hr) |
| PT (1) | PT3145949T (hr) |
| RS (1) | RS60586B1 (hr) |
| SI (1) | SI3145949T1 (hr) |
| UA (1) | UA122127C2 (hr) |
| WO (1) | WO2015177501A1 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102015012334A2 (pt) * | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
| DK3377637T3 (da) | 2016-04-08 | 2020-05-18 | Krystal Biotech Inc | Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden |
| JP2018174874A (ja) * | 2017-04-19 | 2018-11-15 | 国立大学法人 東京医科歯科大学 | 上皮細胞の水分泌機能測定方法 |
| GB201814590D0 (en) * | 2018-09-07 | 2018-10-24 | Oxford Biomedica Ltd | Viral vector production system |
| CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| JP7300764B2 (ja) * | 2018-07-02 | 2023-06-30 | キュラミス カンパニー・リミテッド | 細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途 |
| WO2020009444A1 (ko) * | 2018-07-02 | 2020-01-09 | 서울대학교산학협력단 | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 |
| CA3112627A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
| CN113874513A (zh) * | 2019-03-13 | 2021-12-31 | 世代生物公司 | 非病毒dna载体及其用于表达fviii治疗剂的用途 |
| CN112575034B (zh) * | 2019-09-29 | 2023-04-25 | 济南赛尔生物科技股份有限公司 | 一种治疗a型血友病的产品及应用 |
| US20210189427A1 (en) * | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| AU2021264465A1 (en) * | 2020-04-27 | 2022-12-15 | University Of Iowa Research Foundation | Compositions and methods for the treatment of cystic fibrosis |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| JP2023540705A (ja) | 2020-08-28 | 2023-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 修飾された抗ウイルス結合剤 |
| GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
| GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| JP2024513826A (ja) | 2021-04-02 | 2024-03-27 | クリスタル バイオテック インコーポレイテッド | がん治療のためのウイルスベクター |
| GB202105278D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Cell therapy |
| GB202105276D0 (en) * | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Delivery of gene therapy vectors |
| CN117916383A (zh) * | 2021-07-19 | 2024-04-19 | 2赛文缇生物公司 | 载体制备方法 |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20240024515A1 (en) | 2022-04-11 | 2024-01-25 | Imperial College Of Science, Technology And Medicine | Combination treatment |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| GB202212472D0 (en) * | 2022-08-26 | 2022-10-12 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| WO2024057315A1 (en) | 2022-09-15 | 2024-03-21 | Yeda Research And Development Co. Ltd. | Compositions and methods for virotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360347C (en) * | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| KR100807016B1 (ko) * | 2000-06-01 | 2008-02-25 | 가부시키가이샤 디나벡크 겐큐쇼 | 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터 |
| AU2002327755A1 (en) * | 2001-09-28 | 2003-04-14 | Rush-Presbyterian-St. Luke's Medical Center | Paramyxoviruses as gene transfer vectors to lung cells |
| AU2002343458B2 (en) * | 2001-10-02 | 2008-03-20 | Institut Clayton De La Recherche | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
| SI1950307T1 (sl) * | 2005-10-28 | 2016-02-29 | Id Pharma Co., Ltd. | Transfer gena v epitelijsko matično celico dihalnih poti z uporabo lentivirusnega vektorja, psevdotipiziranega z RNA virusnim spike proteinom |
| GB0606190D0 (en) * | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
| EP1950303A1 (de) | 2007-01-26 | 2008-07-30 | Bayer CropScience AG | Genetisch modifizierte Pflanzen, die eine Stärke mit geringem Amylosegehalt und erhöhtem Quellvermögen synthetisieren |
| DK2191001T3 (en) * | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
-
2014
- 2014-05-21 GB GB1409089.8A patent/GB2526339A/en not_active Withdrawn
-
2015
- 2015-04-23 JP JP2016567082A patent/JP6637444B2/ja active Active
- 2015-04-23 PL PL15720762T patent/PL3145949T3/pl unknown
- 2015-04-23 DK DK15720762.2T patent/DK3145949T3/da active
- 2015-04-23 AU AU2015263150A patent/AU2015263150B2/en active Active
- 2015-04-23 RS RS20200724A patent/RS60586B1/sr unknown
- 2015-04-23 LT LTEP15720762.2T patent/LT3145949T/lt unknown
- 2015-04-23 ME MEP-2020-114A patent/ME03789B/me unknown
- 2015-04-23 EA EA201692361A patent/EA038966B1/ru unknown
- 2015-04-23 HU HUE15720762A patent/HUE051269T2/hu unknown
- 2015-04-23 EP EP15720762.2A patent/EP3145949B1/en active Active
- 2015-04-23 ES ES15720762T patent/ES2805045T3/es active Active
- 2015-04-23 UA UAA201612986A patent/UA122127C2/uk unknown
- 2015-04-23 US US15/312,026 patent/US10704061B2/en active Active
- 2015-04-23 CA CA2947125A patent/CA2947125C/en active Active
- 2015-04-23 SI SI201531275T patent/SI3145949T1/sl unknown
- 2015-04-23 PT PT157207622T patent/PT3145949T/pt unknown
- 2015-04-23 WO PCT/GB2015/051201 patent/WO2015177501A1/en active Application Filing
-
2020
- 2020-06-10 HR HRP20200930TT patent/HRP20200930T1/hr unknown
- 2020-07-03 CY CY20201100617T patent/CY1123413T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS60586B1 (sr) | 2020-08-31 |
| PL3145949T3 (pl) | 2021-01-25 |
| US10704061B2 (en) | 2020-07-07 |
| CA2947125A1 (en) | 2015-11-26 |
| WO2015177501A1 (en) | 2015-11-26 |
| EA201692361A1 (ru) | 2017-05-31 |
| HUE051269T2 (hu) | 2021-03-01 |
| EP3145949B1 (en) | 2020-04-08 |
| EP3145949A1 (en) | 2017-03-29 |
| GB2526339A (en) | 2015-11-25 |
| US20170096684A1 (en) | 2017-04-06 |
| GB201409089D0 (en) | 2014-07-02 |
| ES2805045T3 (es) | 2021-02-10 |
| ME03789B (me) | 2021-04-20 |
| CA2947125C (en) | 2023-02-28 |
| JP6637444B2 (ja) | 2020-01-29 |
| EA038966B1 (ru) | 2021-11-16 |
| UA122127C2 (uk) | 2020-09-25 |
| SI3145949T1 (sl) | 2020-08-31 |
| PT3145949T (pt) | 2020-07-13 |
| AU2015263150A1 (en) | 2016-11-10 |
| LT3145949T (lt) | 2020-08-25 |
| AU2015263150B2 (en) | 2020-04-16 |
| CY1123413T1 (el) | 2021-12-31 |
| DK3145949T3 (da) | 2020-06-29 |
| JP2017521049A (ja) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200930T1 (hr) | Lentivirusni vektori | |
| JP2017521049A5 (hr) | ||
| JP2018531023A5 (hr) | ||
| WO2016168728A3 (en) | Recombinant promoters and vectors for protein expression in liver and use thereof | |
| DK1186667T3 (da) | Kappegendeficient virusvektor af Paramyxoviridae | |
| JP2017205126A5 (hr) | ||
| JP7098521B2 (ja) | レトロウイルス産生のための安定な細胞株 | |
| RU2014100160A (ru) | Векторы генной терапии адренолейкодистрофии и адреномиелонейропатии | |
| DK2970920T3 (en) | SCALABLE MANUFACTURING PROCESS FOR MANUFACTURING RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM | |
| JP2016512700A5 (hr) | ||
| JP2012501182A5 (hr) | ||
| WO2016118642A8 (en) | Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof | |
| HRP20211910T1 (hr) | Mnd promotor himerni antigen receptori | |
| JP2016501531A5 (hr) | ||
| FI2604695T3 (fi) | Replikaatiokyvyttömiä arenavirusvektoreita | |
| RU2017118325A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| EP4373951A1 (en) | Vector manufacturing processes | |
| JP2024504914A (ja) | 高分散性ｈｅｋ２９３ｔ細胞株及びそのスクリーニング方法 | |
| JP2017060502A5 (hr) | ||
| WO2008020331A3 (en) | Polynucleotides allowing the expression and secretion of recombinant hepatitis b surface antigen (hbsag) virus-like particles containing a foreign peptide, their production and use | |
| MX2017006671A (es) | Plásmidos y método para obtener partículas virales. | |
| JP2016530890A5 (hr) | ||
| WO2003029274A3 (en) | Paramyxoviruses as gene transfer vectors to lung cells | |
| WO2021072284A3 (en) | Canine distemper virus hemagglutinin and fusion polypeptides | |
| JP2015530875A5 (hr) |